BioSpace News Archive

Applied UV, Inc. today announced that it has engaged the services of Herrick, Feinstein LLP to investigate potential illegal short selling of the Company’s stock.

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl ® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia.

Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis,

Dr. Reddy’s Laboratories Ltd. today announced the launch of Dr. Reddy’s Difluprednate Ophthalmic Emulsion 0.05%, a therapeutic generic equivalent to Durezol® (Difluprednate Ophthalmic Emulsion 0.05%) in the U.S. market, following the approval by the U.S. Food and Drug Administration (USFDA).

Arbutus Biopharma Corporation today announced that Tram Tran, MD has notified the Company of her intention to resign from the Company’s Board of Directors, effective February 26, 2023.

Welltower Inc. (NYSE: WELL) today announced it will release fourth quarter 2022 financial results after the close of trading on the New York Stock Exchange on Wednesday, February 15, 2023.

Sol-Gel Technologies, Ltd. announced today the pricing of a registered direct offering with Armistice Capital for the sale and purchase of 2,560,000 shares of the Company’s ordinary shares, par value NIS 0.1 (the “Ordinary Shares”), at a purchase price of $5.00 per share, in a registered direct offering (the “Registered Direct Offering”).

Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the SVB Securities Global Biopharma Conference.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to announce a total research and development (R&D) cash receipt of A$6,219,241.

Samsung Biologics, the world’s leading contract development and manufacturing organization, announced strong financial results for the fourth quarter and record-high earnings for the fiscal year 2022.